Hostname: page-component-89b8bd64d-j4x9h Total loading time: 0 Render date: 2026-05-07T12:48:21.288Z Has data issue: false hasContentIssue false

Regression approaches in the test-negative study design for assessment of influenza vaccine effectiveness

Published online by Cambridge University Press:  06 January 2016

H. S. BOND
Affiliation:
WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
S. G. SULLIVAN*
Affiliation:
WHO Collaborating Centre for Reference and Research on Influenza at the Peter Doherty Institute for Infection and Immunity, Melbourne, Australia Fielding School of Public Health, University of California, Los Angeles, CA, USA
B. J. COWLING
Affiliation:
WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China
*
*Author for correspondence: Dr S. G. Sullivan, Peter Doherty Institute for Infection and Immunity, 792 Elizabeth St, Melbourne, Vic 3000, Australia. (Email: sheena.sullivan@influenzacentre.org)
Rights & Permissions [Opens in a new window]

Summary

Influenza vaccination is the most practical means available for preventing influenza virus infection and is widely used in many countries. Because vaccine components and circulating strains frequently change, it is important to continually monitor vaccine effectiveness (VE). The test-negative design is frequently used to estimate VE. In this design, patients meeting the same clinical case definition are recruited and tested for influenza; those who test positive are the cases and those who test negative form the comparison group. When determining VE in these studies, the typical approach has been to use logistic regression, adjusting for potential confounders. Because vaccine coverage and influenza incidence change throughout the season, time is included among these confounders. While most studies use unconditional logistic regression, adjusting for time, an alternative approach is to use conditional logistic regression, matching on time. Here, we used simulation data to examine the potential for both regression approaches to permit accurate and robust estimates of VE. In situations where vaccine coverage changed during the influenza season, the conditional model and unconditional models adjusting for categorical week and using a spline function for week provided more accurate estimates. We illustrated the two approaches on data from a test-negative study of influenza VE against hospitalization in children in Hong Kong which resulted in the conditional logistic regression model providing the best fit to the data.

Information

Type
Original Papers
Copyright
Copyright © Cambridge University Press 2016 
Figure 0

Fig. 1. Plots showing the epidemic curve and the number of vaccinated patients using the three different vaccination scenarios. Solid black lines show the infected susceptibles, dashed black lines show the infections among vaccinated persons and the grey lines show the total vaccine coverage. We assume vaccines become effective 2 weeks after vaccination.

Figure 1

Table 1. Parameters used in the simulation

Figure 2

Table 2. Vaccine effectiveness (VE) and 95% sampling intervals obtained from simulated results using conditional and unconditional maximum-likelihood models under three vaccination scenarios

Figure 3

Fig. 2. Plots showing results of the sensitivity analysis comparing calculated vaccine effectiveness estimates when data are restricted to the influenza epidemic period vs. using entire surveillance period. Data shown are point estimates and sampling intervals for each model.

Figure 4

Fig. 3. Plots showing the sensitivity analysis performed using different combinations of parameter values. VE, Vaccine effectiveness; PV, proportion vaccinated; PI, proportion infected. Data shown are point estimates and sampling intervals for each model.

Figure 5

Table 3. Sensitivity analysis showing the effects of differing the epidemic period for non-influenza viruses. Values shown in table are VE (%) with 95% sampling intervals

Figure 6

Fig. 4. Enrolment of patients and vaccination coverage over calendar time in Hong Kong. (a) Number of enrolled children each week, by laboratory test result. The dark grey bars show the test-negative patients and the light grey bars show the test-positive patients. (b) Vaccine coverage among cases testing negative for influenza virus, smoothed using the Daniel 1 kernel [26].

Figure 7

Table 4. Estimated vaccine effectiveness (VE) under alternative regression models